Elicio Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Elicio is a clinical-stage biotechnology company developing lymph-node-targeted immunotherapies. Its lead candidate, ELI-002, targets KRAS-mutated cancers. The June 1, 2023 merger with Angion was accounted for as a reverse recapitalization, with Former Elicio treated as the accounting acquirer; therefore, results before the merger largely reflect Former Elicio, not the combined company.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $23.8 million | $18.1 million |
| General and administrative expense | $11.9 million | $5.6 million |
| Total operating expenses / loss from operations | $35.7 million | $23.7 million |
| Net loss | $35.2 million | $28.2 million |
| Net loss per share, basic and diluted | $6.96 | $89.27 |
| Cash used in operating activities | $32.7 million | $22.2 million |
| Cash and cash equivalents at year-end | $12.9 million | $6.2 million |
Cash, cash equivalents and restricted cash totaled $14.3 million at December 31, 2023. Current assets were $16.3 million and current liabilities were $9.8 million. Total liabilities were $15.8 million, including $6.9 million of operating lease liabilities; the balance sheet reports no promissory-note balance at year-end. The filing does not provide meaningful product margins, as the company has no product sales.
Financing activities provided $38.6 million in 2023, including $31.6 million of net merger proceeds and approximately $7.0 million from a December common-stock placement. The company reported an accumulated deficit of $142.2 million.
Changes, outlook and material risks
- Year-over-year change: Operating expenses rose 50.6%. R&D increased 31.7%, mainly from ELI-002 manufacturing and clinical-trial costs; G&A more than doubled, largely due to personnel, merger-related professional fees and public-company costs. Net loss increased 24.8%. Other income/expense improved by $5.0 million, primarily because of lower interest expense.
- Going concern and funding: Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. At year-end, management estimated cash would fund planned operations into the third quarter of 2024. The company expects continuing losses and needs additional capital; it may seek equity or debt financing, partnerships, licensing or other transactions. Failure to obtain funding could require reductions or termination of programs or cessation of operations.
- Subsequent financing: After year-end, the company sold 615,363 shares through its ATM program for approximately $5.1 million net. In March 2024, it raised approximately $6.0 million gross through pre-funded warrants sold to an entity controlled by a director. These proceeds post-date year-end and do not, by themselves, establish an updated cash-runway estimate.
- Development outlook: ELI-002’s randomized Phase 2 study in KRAS-mutated pancreatic cancer began dosing in January 2024, with approximately 135 participants planned. Management expected enrollment to complete by year-end 2024 and interim results in Q1 2025. Phase 1A preliminary results were expected in Q2 2024. These are forward-looking targets, not assured outcomes. ELI-007 and ELI-008 remain preclinical.
- Clinical evidence and uncertainty: In the 25-patient AMPLIFY-201 Phase 1 study of the 2-peptide formulation, reported results included KRAS-specific T-cell responses in 84% of patients and median relapse-free survival of 16.3 months for the cohort. The results are early-stage and from a small trial; they do not establish clinical benefit in the ongoing Phase 2 trial. The company does not intend further studies of the 2-peptide formulation.
- Key risks: Besides financing and going-concern risk, the filing highlights clinical and regulatory uncertainty, patient enrollment, dependence on contract manufacturers and CROs, manufacturing scale-up, competition, reliance on MIT-licensed intellectual property, and the need for a companion diagnostic for ELI-002. The company also disclosed material weaknesses in financial-reporting controls and concluded its disclosure controls and internal control over financial reporting were ineffective at year-end. Remediation efforts were underway but not complete.
The independent auditor issued an unqualified opinion on the financial statements, with a separate going-concern emphasis. The auditor was not engaged to audit internal control effectiveness. The company reported no legal proceeding expected to have a material adverse effect and no material cybersecurity incident in the prior three fiscal years.
Important facts for investors to verify
- Whether post-year-end financing and other cash movements extend the disclosed runway, and the company’s current liquidity and funding requirements.
- Progress, enrollment, safety and efficacy of the randomized ELI-002 Phase 2 trial, including whether stated enrollment and interim-analysis timing remains on track.
- Whether early AMPLIFY-201 findings are reproduced in larger, controlled studies; note the small sample and early-stage nature of those results.
- Availability and regulatory progress of the ELI-002 companion diagnostic, and supply continuity from third-party manufacturers, including China-related exposure.
- Progress in remediating the disclosed material weaknesses and whether subsequent filings report effective controls or further deficiencies.
- Potential dilution and resale effects of the December 2023 related-party share issuance, March 2024 pre-funded warrants and ATM sales.